Cancer Cell

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Seed G, Beije N, Yuan W, ..., Carreira S, de Bono J

Cancer Cell 42 (12) 2113-2123.e4 [2024-12-09; online 2024-11-21]

Arian Lundberg DDLS Fellow

Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer.

Calì B, Troiani M, Bressan S, ..., de Bono J, Alimonti A

Cancer Cell 42 (10) 1676-1692.e11 [2024-10-14; online 2024-09-19]

Arian Lundberg DDLS Fellow

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Binder ZA, Thorne AH, Bakas S, ..., Furnari FB, O'Rourke DM

Cancer Cell 34 (1) 163-177.e7 [2018-07-09; online 2018-07-11]

Affiliated researcher

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, ..., Jonkers J, Rottenberg S

Cancer Cell 33 (6) 1078-1093.e12 [2018-06-11; online 2018-06-13]

Affiliated researcher

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Berger AC, Korkut A, Kanchi RS, ..., Levine DA, Akbani R

Cancer Cell 33 (4) 690-705.e9 [2018-04-09; online 2018-04-02]

Affiliated researcher

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.

Hill RM, Kuijper S, Lindsey JC, ..., Chesler L, Clifford SC

Cancer Cell 27 (1) 72-84 [2015-01-12; online 2014-12-18]

Affiliated researcher